Seeking Alpha

Genentech Inc. (DNA)

()

News & PR
Market Currents

Buzz
Twitter: DNA

Business Intelligence
Transcripts
Events
Key Developments

Analysis - Latest Articles by most recent | most commented

The Ugly Decade

Dec 1 • Bespoke Investment Group • 18 Comments
PDL BioPharma: High Dividend Biotech Stock

Aug 17 • Double Dividend Stocks • 5 Comments
Onyx Pharmaceuticals: Good Reasons for Raising Capital, Investors Overly Concerned

Aug 13 • Raymond Chung • 2 Comments
OSI Pharmaceutical Gets a Boost from Cancer Drug

Jul 13 • optionMONSTER • Comment!
Alyeska Favors Energy Producers

Jul 8 • Market Folly • 1 Comment
Comparing Medicine’s Cost and Effectiveness

Jul 1 • Eric Savitz • 6 Comments
Hedge Fund Moore Stakes Out Energy Bets

Jul 1 • Market Folly • 1 Comment
Eminence Making a Lab Services Bet?

Jun 26 • Market Folly • 1 Comment
Life Science Looks to Big Pharma for Funding as Caution Still Reigns

Jun 15 • The Burrill Report • Comment!
Galleon Bets Heavily on the S&P 500

Jun 9 • Market Folly • Comment!
Genentech's 'Good' Subsidy Hardly Helps Economic Development

May 31 • Dr. Dr. Bill Conerly • 1 Comment
Blue Ridge Capital: One Hedge Fund That's Done With Gold

May 27 • Market Folly • 8 Comments
What's John Paulson Buying Now? Hint... Think Gold

May 20 • Market Folly • 12 Comments
Swine Flu: Trade Smartly, Beware the Hype

Apr 30 • Mike Stathis • 23 Comments
Personalized Medicine: The Next Big Thing

Apr 29 • Andrew Mickey • 5 Comments
Galleon's Q408: SPY Pays Off Alongside Reduced Equity Positions

Apr 21 • Market Folly • Comment!
Quantitative Price Action Screen: Features to Look For

Apr 15 • Richard Shaw • 2 Comments
That Was Not a 2:1 Split in BBH

Apr 5 • Ron Rowland • 14 Comments
Q1 2009 Biotech Roundup: The Good, the Bad and the Ugly

Apr 2 • Mark Cifra • 5 Comments
FDA and Clinical Trial Updates: Weight Loss, Diabetes and More

Apr 2 • Mike Havrilla • 3 Comments
Genentech Seals Roche's Dominance of Oncology Market

Apr 1 • EP Vantage • Comment!
Successfully Investing in Biotech: Smaller Companies, Lots of Patience

Apr 1 • Ron Sommer • Comment!
Immunogen: Moving on Up

Mar 27 • Beta Delta • Comment!
Wall Street Breakfast: Must-Know News

Mar 26 • SA Editor Rachael Granby • 11 Comments
Eric Mindich's Eton Park Capital Likes Gold

Mar 26 • Market Folly • 1 Comment
Bear Market Rally Not Over Yet

Mar 22 • Tsachy Mishal • 3 Comments
Good News for Roche and Excellent News For Immunogen

Mar 20 • Ohad Hammer • Comment!
Is the Winner Pfizer, Merck or Roche?

Mar 20 • Larry Rothman • 11 Comments
Moore Capital Investments: Theme Is Economic Recovery

Mar 18 • Market Folly • 4 Comments
Tudor Investment Takes New Positions in Financials, Among Others

Mar 17 • Market Folly • 3 Comments
Where Might Genentech Investors Redeploy $47B?

Mar 16 • Michael Becker • 2 Comments
Big Mergers Could Mean Sweet Gains for Biotech

Mar 13 • Smart Profits Report • 6 Comments
Profitability Propelled the Recent Rally

Mar 13 • Chris Krasowski • 3 Comments
Thursday's Options Recap

Mar 12 • Frederic Ruffy • 1 Comment
Waxman's Bill Is Bad for Biotech

Mar 12 • Zacks.com • 6 Comments
Roche / Genentech Is a Done Deal

Mar 12 • Derek Lowe • 4 Comments
Biotech Dip: Sector Weakness, or Buying Opportunity?

Mar 12 • Hans Wagner • 4 Comments
Wall Street Breakfast: Must-Know News

Mar 12 • SA Editor Rachael Granby • 11 Comments
Preview from Europe: The Horror Show's Alive and Well

Mar 12 • The Mole • 13 Comments
Maverick Capital's 13F Filing for Q408

Mar 12 • Market Folly • 3 Comments
When Will the Genentech Roller Coaster End?

Mar 11 • Mike Huckman • 2 Comments

Genentech Inc. (DNA)

Analysis - Latest Articles by most recent | most commented

The Seeking Alpha 100

Fastest Climbers

Top Commenters

Top Instabloggers

Top StockTalkers